CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Millennium Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited

1:15-cv-00540

Overview

Case Number 1:15-cv-00540
Filing Date 2015-06-25
Status Terminated
Termination Date 2018-03-15
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Sun Pharmaceutical Industries Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Sun Pharma Global FZE Operating Company

Represented By

2 Attorneys Listed

Lori Ann Brewington

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7700

Richards, Layton & Finger, PA, One Rodney Square

Kelly E. Farnan

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7705

Richards, Layton & Finger, PA, One Rodney Square

Sun Pharmaceutical Industries Limited NPE (University / Research)

Represented By

2 Attorneys Listed

Lori Ann Brewington

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7700

Richards, Layton & Finger, PA, One Rodney Square

Kelly E. Farnan

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7705

Richards, Layton & Finger, PA, One Rodney Square

Plaintiff

Millennium Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 9 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2017-04-13
1:17-cv-00422

Millennium Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2017-04-13
1:17-cv-00423

Millennium Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc.

Asserted Patent
Status: DED
U.S. District Court 2016-04-04
1:16-cv-00223

Millennium Pharmaceuticals Inc. v. Actavis LLC

Asserted Patent
Status: DED
U.S. District Court 2015-09-10
1:15-cv-00804

Millennium Pharmaceuticals Inc. v. Hospira, Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-01-14
1:15-cv-00039

Millennium Pharmaceuticals Inc. v. Hetero Labs Limited

Asserted Patent
Status: DED
U.S. District Court 2015-01-14
1:15-cv-00040

Millennium Pharmaceuticals Inc. v. Mylan Laboratories Limited

Asserted Patent
Status: DED
U.S. District Court 2014-01-22
1:14-cv-00093

Millennium Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-22
1:13-cv-00467

Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC

Asserted Patent
Status: DED
U.S. District Court 2012-12-21
1:12-cv-01750

Millennium Pharmaceuticals Inc. v. Actavis Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6713446
Formulation of boronic acid compounds
Filed: 2002-01-25
Issued: 2004-03-30
Expired (Term Ended)
Expires: 2022-01-25
US6958319
Formulation of boronic acid compounds
Filed: 2003-09-18
Issued: 2005-10-25
Expired (Term Ended)
Expires: 2022-04-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(37 total)
Pleading / Complaint

COMPLAINT filed against Sun Pharma Global FZE, Sun Pharmaceutical Industries Inc., Sun Pharmaceutical Industries Limited - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1745833.) - filed by Millennium Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(sar) (Entered: 06/26/2015)

Entry #1 • 2015-06-25
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 06/26/2015)

Entry #2 • 2015-06-25
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 13, 2015. Date of Expiration of Patent: January 25, 2022.Thirty Month Stay Deadline: 11/13/2017. (sar) (Entered: 06/26/2015)

Entry #3 • 2015-06-25
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,713,446 B2; 6,958,319 B2;. (sar) (Entered: 06/26/2015)

Entry #4 • 2015-06-25
1

Disclosure Statement pursuant to Rule 7.1: adding Takeda Pharmaceuticals Company Limited to Millennium Pharmaceuticals Inc., as Corporate Parent filed by Millennium Pharmaceuticals Inc. (sar) Modified on 6/26/2015 (rwc). (Entered: 06/26/2015)

Entry #5 • 2015-06-25
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc